Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…

Stock Predictive Oncology Inc. POAI

Predictive Oncology Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -57.84%

Price change 2019 → 2020: -71.95%

Price change 2020 → 2021: 30.05%

Price change 2021 → 2022: -67.75%

Price change 2022 → 2023: -46.42%

Price change 2023 → 2024: -75.08%

Price change 2024 → 2025: -41.87%

Price change 2025 → 2026: -34.55%

Price change 2026 (year to date): -33.99%

Financial growth

Revenue CAGR (8 years): -29.25%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.03

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.38

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 46.51% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 03/05/2010
ISIN code
US74039M4087
Workforce
23
full-time employees
Chief executive
Raymond F. Vennare

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Predictive Oncology Inc.

Is Predictive Oncology Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US74039M4087).

How many employees does Predictive Oncology Inc. have?

23 full-time employees according to the latest published profile.

Who runs Predictive Oncology Inc.?

Raymond F. Vennare is the company's chief executive.